2

3

## WHAT IS CLAIMED IS:

1	1. A timed-release compression-coated solid composition for oral
2	administration, said composition comprising:
3	a) a core tablet comprising a drug and a freely erodible filler, wherein said
4	core tablet is capable of approximately 40 to approximately 90% erosion; and
5	b) an outer layer, said outlayer is made from a hydrogel-forming polymer
6	substance and a hydrophilic base, wherein said outer layer optionally contains a drug.
1	2. The timed-release compression-coated solid composition for oral
2	administration according to claim 1, wherein the outer layer comprises a drug and wherein
3	the outer layer essentially does not contain the same drug as the core tablet drug.
1	3. The timed-release compression-coated solid composition for oral
2	administration according to claim 1, wherein there is approximately 75 wt% or less of said
3	drug, approximately 5 to approximately 80 wt% freely erodible filler, approximately 10 to
4	approximately 95 wt% hydrogel-forming polymer substance, and approximately 5 to
5	approximately 80 wt% hydrophilic base.
1	4. The timed-release compression-coated solid composition for oral
2	administration according to claim 1, wherein the freely erodible filler is 1 or 2 or more
3	selected from the group consisting of malic acid, citric acid, tartaric acid, polyethylene
4	glycol, sucrose, and lactulose.
1	5. The timed-release compression-coated solid composition for oral

- administration according to claim 1, wherein the freely erodible filler is 1 or 2 or more selected from the group consisting of malic acid, citric acid and tartaric acid.
- 1 6. The timed-release compression-coated solid composition for oral
  2 administration according to claim 1, wherein the freely erodible filler for a basic drug is 1 or
  3 2 or more selected from the group consisting of malic acid, citric acid and tartaric acid.
- 7. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the freely erodible filler for an acidic or neutral drug is 1 or 2 or more selected from the group consisting of polyethylene glycol, sucrose or lactulose.

- 1 8. The timed-release compression-coated solid composition for oral 2 administration according to claim 1, wherein the hydrogel-forming polymer substance 3 contains at least one type of polyethylene oxide.
- 9. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the hydrogel-forming polymer substance is 1 or 2 or more having a viscosity-average molecular weight of 2,000,000 or higher and/or a viscosity in an aqueous 1% solution (25°C) of 1,000 cp or higher.
  - 10. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the core tablet contains hydrogel-forming polymer substance.
  - 11. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the hydrophilic base is 1 or 2 or more having solubility such that the amount of water needed to dissolve 1 g base is 5 mL or less.
  - 12. The timed-release compression-coated solid composition for oral administration according to claim 11, wherein the hydrophilic base is 1 or 2 or more selected from the group consisting of polyethylene glycol, sucrose, and lactulose.
  - 13. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the hydrogel-forming polymer substance is at least 1 type of polyethylene oxide and further contains red ferric oxide and/or yellow ferric oxide.
  - 14. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein a drug is brought to be effectively released or absorbed in the lower digestive tract.
  - 15. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein a drug is brought to be effective for chronopharmacotherapy.
  - 16. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein a drug is metabolized by cytochrome P-450.

-G1 \*

1

2

1

2

3

1

2

1

2

4

1

2

3

4

- 1 The timed-release compression-coated solid composition for oral 2 administration according to claim 1, wherein a drug has the effect of inhibiting metabolism 3 by cytochrome P-450.
  - 18. The timed-release compression-coated solid composition for oral administration according to claim 16, wherein the drug is metabolized by CYP3A4.
- 1 19. The timed-release compression-coated solid composition for oral 2 administration according to claim 17, wherein the drug has the effect of inhibiting 3 metabolism by CYP3A4.
  - 20. The timed-release compression-coated solid composition for oral administration according to claim 1, wherein the drug is 4'-[(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or its salt.
  - 21. A method of timed release of a drug, whereby the composition in claim 1 is orally administered.
  - 22. A method for alleviating undesirable drug interaction between a drug and other drugs used concomitantly that employ the same route for drug absorption, distribution, metabolism or excretion *in vivo* in humans, whereby the composition in claim 1 is orally administered.
- 1 23. A method of alleviating undesirable drug interaction with between a 2 drug having the effect of inhibiting drug metabolism *in vivo* in humans and another drug 3 according to claim 20 used concomitantly, whereby the composition in claim 1 is used.
  - 24. In a hydrogel-forming compression-coated solid pharmaceutical preparation comprising: a core tablet containing drug and outer layer made from hydrogel-forming polymer substance and hydrophilic base, the improvement which comprises a timed-release compression-coated solid composition according to claim 1.
- 1 25. In a hydrogel-forming compression-coated solid pharmaceutical preparation comprising:

3	a core tablet containing drug and outer layer made from hydrogel-forming
4	polymer substance and hydrophilic base, the improvement which comprises a timed-release
5	compression-coated solid composition for oral administration, said composition comprising
6	(1) a drug and freely erodible filler are mixed with the core tablet;
7	(2) the percentage erosion of the core tablet is approximately 40 to
8	approximately 90%; and
9	(3) the outer layer essentially does not contain the same drug as the above-
10	mentioned drug.
1	26. The timed-release compression-coated solid composition for oral
2	administration according to claim 25, wherein the drug is 4'-[(2-methyl-1,4,5,6-
3	tetrahydroimidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide or its salt.